
Nobel Prize Laureate Michael Houghton, PhD, discusses the arduous journey to find the virus and a subsequent investigational vaccine designed to prevent hepatitis C (HCV).
Nobel Prize Laureate Michael Houghton, PhD, discusses the arduous journey to find the virus and a subsequent investigational vaccine designed to prevent hepatitis C (HCV).
Injection drug users who received accessible care treatment at a syringe service program were almost 3 times as likely to complete their hepatitis C treatment than people who received usual care.
Catch up on all the important news and clinical care topics you may have missed this week.
Reviewers weigh evidence for the benefit of oral PrEP protection from HIV with risk of exacerbating hepatitis B.
A new report underscores a persistent problem of patients not receiving antivirals despite their high curative rate.
A biotech company is utilizing this platform to rid people of the virus using a technology that differs from CRISPR-Cas9.
Rates of hepatitis C reinfection were low among people receiving opioid agonist therapy, according to a new study, which highlights the importance of risk reduction interventions and HCV treatment for people who inject drugs and people receiving opioid agonist therapy.
WHO guidelines on HIV, hepatitis and STIs focus on populations with high risk of infections but low inclusion in prevention and treatment programs.
WHO issues new HCV treatment recommendations that include "radical simplification" of care pathways, in pursuit of testing and treatment goals.
At AIDS 2022, Gilead presented data suggesting Biktarvy was a safe and effective complete HIV treatment regimen, including for those coinfected with hepatitis B.
What steps need taken to end viral hepatitis by 2030? “It all comes down to testing,” said Carl Schmid, executive director of the HIV+Hepatitis Policy Institute.
Implicating adenovirus for hepatitis of unknown cause in children is confounded by its absence in some cases, and from all tested hepatic tissue.
Viral hepatitis “can and should be managed within primary care,” says Dr. Thomas Robertson.
The FDA and other health agencies are investigating fresh organic strawberries, branded as FreshKampo or HEB, that are believed to be the source of hepatitis A infections in the US and Canada.
A shorter dosing period and no extra risk of suffering acute myocardial infarction means the newer 2-dose hepatitis B vaccine is an attractive option for protection.
The cases are in the pediatric population and come from 11 countries in the WHO European Region and 1 country in the WHO Region of the Americas.
The federal agency's new guidelines for adults between 19-59 years replaces risk-based recommendations.
In this latest episode of Contagion Community, we interview Dr. Jacinda Abdul-Mutakabbir about vaccine equality vs vaccine equity as well as her experience on a COVID-19 vaccine drive to increase vaccinations in communities of color.
Incidence of hepatitis B has fallen in the Asia and Pacific region, but progress against hepatitis C in the region has lagged and morbidity and mortality continued to rise, underscoring a need to improve diagnosis and linkage of care, according to a recent report.
The CDC’s Advisory Committee on Immunization Practices voted to recommend hepatitis B, orthopoxviruses, and Ebola vaccines to certain populations, as well as approving 2022 immunization schedules for children, adolescents, and adults.
HIV coinfection was associated with a 3.7-fold increase in the risk of non-liver-related cancer among patients with hepatitis C virus infection, a new study found.
Infection with hepatitis B (HBV) can be challenging. What will patients accept in exchange for the chance of a functional care?
CDC report chronicles 20 incidents of HBV infection among recipients between 2014 and 2019.
New shot fills a vital need, given poor efficacy of earlier options, researchers say.
With its mRNA COVID-19 vaccine authorized, the company is employing the technology to take aim at a variety of pathogens.